Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 08, 2022

SELL
$144.95 - $152.29 $7.44 Million - $7.81 Million
-51,300 Reduced 21.82%
183,768 $27.8 Million
Q2 2022

Aug 12, 2022

BUY
$83.14 - $145.99 $13.5 Million - $23.8 Million
162,825 Added 225.39%
235,068 $34.3 Million
Q1 2022

May 13, 2022

BUY
$110.08 - $142.92 $1,100 - $1,429
10 Added 0.01%
72,243 $8.57 Million
Q4 2021

Feb 11, 2022

SELL
$99.73 - $148.48 $1.71 Million - $2.54 Million
-17,117 Reduced 19.16%
72,233 $9.96 Million
Q3 2021

Nov 10, 2021

BUY
$98.85 - $138.91 $4.13 Million - $5.8 Million
41,748 Added 87.7%
89,350 $12.4 Million
Q2 2021

Aug 16, 2021

BUY
$65.78 - $105.02 $1.1 Million - $1.75 Million
16,663 Added 53.86%
47,602 $4.62 Million
Q1 2021

May 13, 2021

BUY
$64.07 - $91.75 $447,016 - $640,139
6,977 Added 29.12%
30,939 $2.11 Million
Q4 2020

Feb 16, 2021

BUY
$65.07 - $98.24 $1.56 Million - $2.35 Million
23,962 New
23,962 $2.05 Million
Q1 2020

May 14, 2020

SELL
$27.51 - $57.29 $242,638 - $505,297
-8,820 Closed
0 $0
Q4 2019

Feb 13, 2020

SELL
$40.86 - $57.65 $206,915 - $291,939
-5,064 Reduced 36.47%
8,820 $481,000
Q3 2019

Nov 13, 2019

SELL
$37.38 - $49.47 $2.18 Million - $2.88 Million
-58,230 Reduced 80.75%
13,884 $579,000
Q2 2019

Aug 08, 2019

BUY
$39.79 - $67.01 $459,972 - $774,635
11,560 Added 19.09%
72,114 $3.16 Million
Q1 2019

May 13, 2019

SELL
$34.52 - $53.29 $16,189 - $24,993
-469 Reduced 0.77%
60,554 $3.12 Million
Q4 2018

Feb 14, 2019

BUY
$29.75 - $42.9 $1.82 Million - $2.62 Million
61,023 New
61,023 $2.26 Million

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $3.18B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Allianz Asset Management Gmb H Portfolio

Follow Allianz Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.